Trials / Terminated
TerminatedNCT02711345
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
A Phase I Dose Finding Study of Oral LTT462 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LTT462 | ERK Inhibitor |
Timeline
- Start date
- 2016-04-15
- Primary completion
- 2018-11-21
- Completion
- 2018-11-21
- First posted
- 2016-03-17
- Last updated
- 2019-09-19
- Results posted
- 2019-09-19
Locations
7 sites across 6 countries: United States, Germany, Japan, Singapore, Spain, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02711345. Inclusion in this directory is not an endorsement.